A federal judge decided not to certify a class action against GlaxoSmithKline, the makers of Wellbutrin.  The consumer and indirect purchaser class action sought to show that there was a plan to maintain higher prices of the drug Wellbutrin.  A federal judge refused on the grounds that there wasn’t enough to prove that each member was affected.  This has been touted as a “significant win for big pharmaceutical firms.”

Interested in learning more?  PLI held its annual seminar Developments in Pharmaceutical and Biotech Patent Law 2010.  The accompanying course handbook is now available and provides valuable insight.